Recovering scientist turned early stage VC A biotech optimist fighting gravity

Of Abundance And Scarcity In Venture Capital
March 13, 2017

As a biotech investor, it’s been fascinating to watch the Snapchat IPO and the fanfare around this $25B sensation following its offering as a “camera” company. As one of the big tech unicorns, it’s justifiably gotten considerable attention in the

1 Comment

VC-Backed Biotech Ecosystem: A Market In Healthy Equilibrium
March 10, 2017

Despite the volatility of biotech stocks in the public markets, the VC-backed private biotech ecosystem has been in remarkable equilibrium for much of the last decade. e·qui·lib·ri·um. noun.  a state in which opposing forces or influences are balanced. As I’ve noted


From Poisons To Pills: Peptides
February 10, 2017

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. When a taxi driver finds out the name of my company, I am inevitably asked, “What does Bicycle Therapeutics


Helping Others Conquer The Mountain
February 8, 2017

Snow sports are a passion of mine; almost any day up on a mountain is a great day. By combining this passion with a bigger purpose, I’ve recently tapped into a true vein of inspiration, integrating both my professional and

Leave a comment

Seven Important Policy Agenda Items For BioPharma
January 31, 2017

President Trump’s tenure as the 45th POTUS has begun with even more fireworks than most pundits predicted – protests, marches, bans, and lots of other drama. The coastal Twitter/Facebook bubbles are exploding with anger and rage, while the Trump populists

1 Comment

Talent In The Biotech Gig Economy
January 31, 2017

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Walking the streets of Union Square in mid-January torrential rain, we had the good fortune of sharing the


Delinia Delivers An Exciting Autoimmune Therapy To Celgene
January 26, 2017

Today Celgene announced its acquisition of Delinia for $300 million upfront, and up to $475 million in milestones, adding to its growing portfolio of novel immunology medicines. Delinia’s rapid trajectory over the past fifteen months has been exciting to watch: this

Leave a comment

Alzheimer’s Research: Diversity Now
January 19, 2017

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics and Atlas EIR, as part of the From The Trenches feature of LifeSciVC.   In my February 2016 post, I wrote “if some of the current generation of high-profile,

1 Comment

After the San Francisco Rain: Looking On The Bright Side In 2017
January 18, 2017

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC. The biotech industry was reeling after the 2016 J.P. Morgan Healthcare Conference, with many commentators foretelling doom in the

1 Comment

Potential Breakthrough Option For Parkinson’s: LTI Partners With Allergan
January 9, 2017

Today Allergan announced a transformative deal with Lysosomal Therapeutics (LTI), an emerging biotech focused on Parkinson’s Disease through an understanding of human genetics and sphingolipid biology (here). This deal brings a new chapter for LTI as we move our lead

1 Comment

Crystal Ball Gazing: Biotech Predictions for 2017
January 5, 2017

Good riddance to 2016, and a warm embrace to 2017 – or so is the sentiment of most biotech investors as they head into the 35th annual JPM Healthcare Conference. Many have bemoaned last year as an abysmal one for

Leave a comment

Positive Impact Of External Sourcing On Pharma R&D Productivity
December 16, 2016

Pharma R&D productivity continues to be a critical issue for the industry. Making smart investments in R&D requires an understanding of the risk and return drivers across the product development cycle, as well as some good fortune. This week the

Leave a comment